Mabwell(SH:688062) Zhong Guo Ji Jin Bao·2025-09-01 05:07Market Overview - On September 1, the A-share market experienced fluctuations, with the Shanghai Composite Index rising by 0.12%, the Shenzhen Component Index by 0.11%, and the ChiNext Index by 0.55% [1] - The total trading volume for the market reached 1.85 trillion yuan, slightly lower than the previous day, with over 3,100 stocks rising [1] Key Stocks and Sectors - The top trading stock was Cambrian (688256) with a trading volume of 18.6 billion yuan, followed by Xinyi (300502), Zhongji (300308), and Dongfang Caifu (300059), each exceeding 10 billion yuan in trading volume [1][2] - The precious metals, innovative pharmaceuticals, film and television, tourism, and storage chip sectors saw significant gains, while insurance, military equipment, securities, and airport shipping sectors experienced pullbacks [2] Precious Metals Sector - The precious metals sector surged, with stocks like Haixing (603115), Jintong (601958), and Shengda Resources (000603) hitting the daily limit, while Hunan Gold (002155) and Luoyang Molybdenum (603993) also saw gains [4] - The rise in precious metals is attributed to the recent increase in the U.S. core PCE index, which aligns with expectations for a Federal Reserve rate cut, enhancing the appeal of precious metals as safe-haven assets amid geopolitical risks and trade tensions [4][6] Innovative Pharmaceuticals Sector - The innovative pharmaceutical sector showed strong performance, with Maiwei Bio (688062) hitting the daily limit and other stocks like Baihua Pharmaceutical (600721) and First Pharmaceutical (600833) also experiencing significant gains [7][8] - Maiwei Bio announced the approval of its two biosimilar products in Pakistan, marking a significant milestone as the first biosimilar approved in the country, and has also entered a licensing agreement with Calico Life Sciences for global rights outside Greater China [9] - The recent adjustments in the national medical insurance catalog are expected to increase the attractiveness of innovative drugs, with a focus on new drugs and unique products [9]